ObsEva Files half Year 2023 Financial Statements ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...

Innate Pharma Reports First Half 2020 Financial Results and Business Update Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoidesMonalizumab Phase 3 study expected to initiate in the second half of 2020,...